Hervé Avet‐Loiseau

54.3k total citations · 4 hit papers
374 papers, 17.0k citations indexed

About

Hervé Avet‐Loiseau is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Hervé Avet‐Loiseau has authored 374 papers receiving a total of 17.0k indexed citations (citations by other indexed papers that have themselves been cited), including 307 papers in Hematology, 236 papers in Molecular Biology and 123 papers in Oncology. Recurrent topics in Hervé Avet‐Loiseau's work include Multiple Myeloma Research and Treatments (293 papers), Protein Degradation and Inhibitors (112 papers) and Peptidase Inhibition and Analysis (61 papers). Hervé Avet‐Loiseau is often cited by papers focused on Multiple Myeloma Research and Treatments (293 papers), Protein Degradation and Inhibitors (112 papers) and Peptidase Inhibition and Analysis (61 papers). Hervé Avet‐Loiseau collaborates with scholars based in France, United States and United Kingdom. Hervé Avet‐Loiseau's co-authors include Jean‐Luc Harousseau, Philippe Moreau, Régis Bataille, Michel Attal, Thierry Façon, Nikhil C. Munshi, Stéphane Minvielle, Florence Magrangeas, Pieter Sonneveld and Jesús F. San Miguel and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Hervé Avet‐Loiseau

358 papers receiving 16.7k citations

Hit Papers

International Staging System for Multiple Myeloma 2005 2026 2012 2019 2005 2017 2013 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. International Staging System for Multiple Myeloma
    2005 1.9k citations Jesús F. San Miguel, Mario Boccadoro et al. Journal of Clinical Oncology profile →
  2. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 518 citations Philippe Moreau, Jesús F. San Miguel et al. profile →
  3. IMWG consensus on risk stratification in multiple myeloma
    2013 413 citations Nikhil C. Munshi, Jesús F. San Miguel et al. Leukemia profile →
  4. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
    2021 236 citations Mehmet Samur, Mariateresa Fulciniti et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hervé Avet‐Loiseau France 67 12.7k 11.3k 7.4k 2.7k 1.9k 374 17.0k
Faith E. Davies United Kingdom 68 13.4k 1.1× 11.5k 1.0× 7.8k 1.1× 2.3k 0.8× 1.8k 0.9× 422 18.5k
Jean‐Luc Harousseau France 69 11.0k 0.9× 8.8k 0.8× 7.0k 0.9× 2.6k 0.9× 2.2k 1.2× 319 15.8k
Sagar Lonial United States 70 11.9k 0.9× 12.3k 1.1× 8.8k 1.2× 2.0k 0.7× 1.6k 0.8× 691 18.9k
Thierry Façon France 69 17.1k 1.4× 13.1k 1.2× 10.6k 1.4× 3.4k 1.2× 1.3k 0.7× 458 21.9k
Mario Boccadoro Italy 60 10.9k 0.9× 8.3k 0.7× 7.4k 1.0× 2.2k 0.8× 1.7k 0.9× 479 15.9k
Hervé Dombret France 67 13.5k 1.1× 7.2k 0.6× 4.1k 0.6× 3.7k 1.3× 1.3k 0.7× 377 18.9k
P. Leif Bergsagel United States 68 10.1k 0.8× 12.0k 1.1× 5.6k 0.7× 2.1k 0.8× 1.7k 0.9× 270 16.8k
Michel Attal France 66 13.2k 1.0× 8.4k 0.7× 7.4k 1.0× 1.8k 0.7× 1.5k 0.8× 322 16.2k
Régis Bataille France 71 10.0k 0.8× 8.5k 0.8× 7.5k 1.0× 2.5k 0.9× 2.0k 1.0× 269 16.9k
Joan Bladé Spain 61 12.1k 1.0× 9.3k 0.8× 6.9k 0.9× 2.4k 0.9× 997 0.5× 324 14.8k

Countries citing papers authored by Hervé Avet‐Loiseau

Since Specialization
Citations

This map shows the geographic impact of Hervé Avet‐Loiseau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hervé Avet‐Loiseau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hervé Avet‐Loiseau more than expected).

Fields of papers citing papers by Hervé Avet‐Loiseau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hervé Avet‐Loiseau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hervé Avet‐Loiseau. The network helps show where Hervé Avet‐Loiseau may publish in the future.

Co-authorship network of co-authors of Hervé Avet‐Loiseau

This figure shows the co-authorship network connecting the top 25 collaborators of Hervé Avet‐Loiseau. A scholar is included among the top collaborators of Hervé Avet‐Loiseau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hervé Avet‐Loiseau. Hervé Avet‐Loiseau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Touzeau, Cyrille, Aurore Perrot, Cyrille Hulin, et al.. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 143(20). 2029–2036. 28 indexed citations
2.
Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations
3.
Samur, Mehmet, Marco Roncador, Anıl Aktaş Samur, et al.. (2023). High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 141(14). 1724–1736. 22 indexed citations
4.
Stong, Nicholas, Fadi Towfic, Mehmet Samur, et al.. (2022). The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 141(13). 1574–1583. 21 indexed citations
5.
Kassem, Sahar, Nizar El-Murr, Nadège Carrié, et al.. (2022). SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood. 139(8). 1160–1176. 17 indexed citations
6.
Terpos, Evangelos, Monika Engelhardt, Gordon Cook, et al.. (2020). Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 34(8). 2000–2011. 81 indexed citations
7.
Amatangelo, Michael, Oliver Van Oekelen, Adeeb Rahman, et al.. (2019). Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients. Blood. 134(Supplement_1). 1775–1775. 9 indexed citations
8.
Bruinink, Davine Hofste op, Vincent van der Velden, Mark van Duin, et al.. (2017). The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow. Blood. 130. 4368–4368.
9.
Furchtgott, Leon, Arnold Bolomsky, Fred K. Gruber, et al.. (2017). Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation. Blood. 130. 3029–3029. 2 indexed citations
10.
Magrangeas, Florence, Rowan Kuiper, Hervé Avet‐Loiseau, et al.. (2016). A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research. 22(17). 4350–4355. 30 indexed citations
11.
Adamia, Sophia, Benjamin Haibe‐Kains, Patrick M. Pilarski, et al.. (2013). A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. Clinical Cancer Research. 20(5). 1135–1145. 79 indexed citations
12.
Corre, Jill, Nicolas Espagnolle, Benjamin Hébraud, et al.. (2012). Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research. 72(6). 1395–1406. 76 indexed citations
13.
Fulciniti, Mariateresa, Samirkumar B. Amin, Puru Nanjappa, et al.. (2011). Significant Biological Role of Sp1 Transactivation in Multiple Myeloma. Clinical Cancer Research. 17(20). 6500–6509. 42 indexed citations
14.
Harousseau, J. L., Hervé Avet‐Loiseau, J. Y. Mary, et al.. (2010). Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma. 95. 451. 4 indexed citations
15.
Avet‐Loiseau, Hervé, Florent Malard, L. Campion, et al.. (2010). Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood. 117(6). 2009–2011. 92 indexed citations
16.
Avet‐Loiseau, Hervé, Xavier Leleu, Murielle Roussel, et al.. (2010). Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology. 28(30). 4630–4634. 298 indexed citations
17.
Harousseau, Jean‐Luc, Michel Attal, & Hervé Avet‐Loiseau. (2009). The role of complete response in multiple myeloma. Blood. 114(15). 3139–3146. 148 indexed citations
18.
19.
Fiche, Maryse, Hervé Avet‐Loiseau, Marie‐Françoise Heymann, et al.. (1999). Genetic alterations in early‐onset invasive breast carcinomas: Correlation of c‐erbB‐2 amplification detected by fluorescence In situ hybridization with p53 accumulation and tumor phenotype. International Journal of Cancer. 84(5). 511–515. 1 indexed citations
20.
Bonnet, Fabrice, P. Mercié, Philippe Morlat, et al.. (1997). [Isolated involvement of the trigeminal nerve of sarcoidosis origin].. PubMed. 153(1). 59–61. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Faith E. Davies Breakdown of academic impact, for papers by Jean‐Luc Harousseau Breakdown of academic impact, for papers by Sagar Lonial Breakdown of academic impact, for papers by Thierry Façon Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by Hervé Dombret Breakdown of academic impact, for papers by P. Leif Bergsagel Breakdown of academic impact, for papers by Michel Attal Breakdown of academic impact, for papers by Régis Bataille Breakdown of academic impact, for papers by Joan Bladé
Rankless by CCL
2026